AstraZenca Pharma India
ASTRAZEN
Quick Bite
Price To Earnings Ratio 96.62 | Sector PE 65.47 |
PB Ratio 22.02 | Sector PB 8.88 |
EPS 64.60 | Dividend Yield 0.45 |
Today's Volume 6.232 K | 5 Day Avg. Volume 34.707 K |
PEG Ratio 1.54 | Market Cap. ₹ 16,930.00 Cr. |
Returns Comparison
| Time | ASTRAZEN | VS | Industry |
|---|---|---|---|
| 1 Day | 1.53% | 0.77% | |
| 1 Week | -10.81% | 0.71% | |
| 1 Month | -10.45% | -1.18% | |
| 6 Months | -0.24% | 14.01% | |
| 1 Year | 29.13% | 45.26% |
Technical Trend
Pivot Levels
Moving Averages
| Period (Days) | SMA | Indication |
|---|---|---|
| 10 | 6772.07 | Bearish |
| 20 | 7027.82 | Bearish |
| 30 | 7153.24 | Bearish |
| 50 | 7159.84 | Bearish |
| 100 | 7124.19 | Bearish |
| 200 | 6643.34 | Bearish |
Shareholding Updates
Cash Flow
| Annual | FY 2024 | FY 2023 | FY 2022 | ||||
|---|---|---|---|---|---|---|---|
| Operating Activities | 27.87 | 58.29 | 100.80 | ||||
| Investing Activities | 21.74 | 18.11 | 4.74 | ||||
| Financing Activities | -44.38 | -24.48 | -9.46 | ||||
| Net Cash Flow | 5.23 | 51.92 | 96.08 |
All Figures in ₹ Cr., unless mentioned otherwise
Ratios
Income Statement
Balance Sheet
Peer Comparison
| Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
|---|---|---|---|---|---|
| AstraZenca Pharma India | 1.53 | -10.81 | -10.45 | -0.24 | 29.13 |
| Aarti Drugs | -0.63 | -2.71 | -6.39 | -2.06 | 3.37 |
| Abbott India | 0.97 | -0.59 | -4.83 | 2.07 | 19.12 |
| Advanced Enzyme Tech | -0.69 | -1.78 | -15.19 | -6.13 | 14.5 |
| Ajanta Pharmaceuticals | 0.96 | 5.5 | 1.86 | 13.58 | 47.38 |
About AstraZenca Pharma India
AstraZenca Pharma India Share Price
AstraZeneca Pharma India Limited is an Indian biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolic; oncology and respiratory diseases. The company operates through the healthcare segment. The company manufactures, markets and distributes pharmaceuticals and provides clinical research services to a foreign group company. Its therapeutic offering in the CVRM business includes Forxiga (Dapagliflozin) in heart failure and chronic kidney disease. Its approvals in the oncology business include Imfinz (Durvalumab) for the treatment of bile duct carcinoma and Lynparza (Olaparib) for early breast cancer. The company has a range of oral diabetes medications that fall into two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The company's DPP4 offering consists of the Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metform) brands.
AstraZenca Pharma India FAQs
How to Buy AstraZenca Pharma India Share?
What's AstraZenca Pharma India share price today?
What is the Market Cap of AstraZenca Pharma India?
What is the PE and PB ratio of AstraZenca Pharma India?
What is the 52 Week High and Low of AstraZenca Pharma India Share?